Pathogenesis of IgA Nephropathy: Omics Data Inform Glycomedicine

Overview

Journal Nephrology (Carlton)

Specialty Nephrology

Date 2024 Sep 27

PMID 39327757

Authors

Jan Novak

Affiliations

Soon will be listed here.

References

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr A, Renfrow M . The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011; 22(10):1795-803. PMC: 3892742. DOI: 10.1681/ASN.2011050464. View

Stewart T, Takahashi K, Whitaker R, Raska M, Placzek W, Novak J . IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2. Glycobiology. 2019; 29(7):543-556. PMC: 6583770. DOI: 10.1093/glycob/cwz007. View

Wandall H, Irazoqui F, Tarp M, Bennett E, Mandel U, Takeuchi H . The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology. 2007; 17(4):374-87. DOI: 10.1093/glycob/cwl082. View

Berger J, HINGLAIS N . [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris). 1968; 74(9):694-5. View

Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N . Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun. 2021; 118:102593. PMC: 7997636. DOI: 10.1016/j.jaut.2021.102593. View

Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Drame M . Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int. 2015; 88(4):815-22. DOI: 10.1038/ki.2015.158. View

Kiryluk K, Novak J . The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014; 124(6):2325-32. PMC: 4089454. DOI: 10.1172/JCI74475. View

Ohyama Y, Yamaguchi H, Ogata S, Chiurlia S, Cox S, Kouri N . Racial heterogeneity of IgA1 hinge-region -glycoforms in patients with IgA nephropathy. iScience. 2022; 25(11):105223. PMC: 9583103. DOI: 10.1016/j.isci.2022.105223. View

Stewart T, Takahashi K, Xu N, Prakash A, Brown R, Raska M . Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases. Glycobiology. 2020; 31(5):540-556. PMC: 8176776. DOI: 10.1093/glycob/cwaa111. View

10.

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K . The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012; 82(7):790-6. PMC: 3443545. DOI: 10.1038/ki.2012.197. View

11.

Jemelkova J, Stuchlova Horynova M, Kosztyu P, Zachova K, Zadrazil J, Galuszkova D . GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy. Kidney Int Rep. 2023; 8(5):1068-1075. PMC: 10166743. DOI: 10.1016/j.ekir.2023.02.1072. View

12.

Daniel E, Las Rivas M, Lira-Navarrete E, Garcia-Garcia A, Hurtado-Guerrero R, Clausen H . Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation. Glycobiology. 2020; 30(11):910-922. PMC: 7581654. DOI: 10.1093/glycob/cwaa036. View

13.

Yamada K, Huang Z, Raska M, Reily C, Anderson J, Suzuki H . Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy. Kidney Dis (Basel). 2020; 6(3):168-180. PMC: 7265702. DOI: 10.1159/000505748. View

14.

Yamada K, Huang Z, Reily C, Green T, Suzuki H, Novak J . LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy. Kidney Int Rep. 2024; 9(2):423-435. PMC: 10851019. DOI: 10.1016/j.ekir.2023.11.003. View

15.

Maillard N, Wyatt R, Julian B, Kiryluk K, Gharavi A, Fremeaux-Bacchi V . Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015; 26(7):1503-12. PMC: 4483595. DOI: 10.1681/ASN.2014101000. View

16.

Liu L, Khan A, Sanchez-Rodriguez E, Zanoni F, Li Y, Steers N . Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Commun. 2022; 13(1):6859. PMC: 9651905. DOI: 10.1038/s41467-022-34456-6. View

17.

Ohyama Y, Renfrow M, Novak J, Takahashi K . Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know. J Clin Med. 2021; 10(16). PMC: 8396900. DOI: 10.3390/jcm10163467. View

18.

Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H . New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis (Basel). 2015; 1(1):8-18. PMC: 4640461. DOI: 10.1159/000382134. View

19.

Tomana M, Novak J, Julian B, Matousovic K, Konecny K, Mestecky J . Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999; 104(1):73-81. PMC: 408399. DOI: 10.1172/JCI5535. View

20.

Yamada K, Huang Z, Raska M, Reily C, Anderson J, Suzuki H . Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney Int Rep. 2017; 2(6):1194-1207. PMC: 5733772. DOI: 10.1016/j.ekir.2017.07.002. View